ID: h-cross-synth-snca-synucleinopathy
Hypothesis

SNCA conformer propagation across PD, DLB, and MSA

Shared mechanism across PD, DLB, MSA: SNCA mutations and alpha-synuclein inclusions define neuronal Lewy pathology in PD/DLB, while MSA shows oligodendroglial alpha-synuclein inclusions.
🧬 SNCA🩺 multi🎯 Composite 82%💱 $0.53▲2.5%validated
neurodegeneration
EvidenceStrong (88%)📖 14 cit🗣 1 debates 4 support 2 oppose
⚠ Low Validation Senate Quality Gates →
Mechanistic 0.90 (15%) Evidence 0.84 (15%) Novelty 0.82 (12%) Feasibility 0.68 (12%) Impact 0.86 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.35 (8%) 0.820 composite

🧪 Overview

Shared mechanism across PD, DLB, MSA: SNCA mutations and alpha-synuclein inclusions define neuronal Lewy pathology in PD/DLB, while MSA shows oligodendroglial alpha-synuclein inclusions. A shared misfolded-alpha-synuclein seeding axis likely diverges by host cell proteostasis and lipid environment, explaining overlapping proteinopathy with distinct anatomy.

Falsifiable prediction: Patient-derived alpha-synuclein seeds from PD/DLB and MSA should induce different neuronal-versus-oligodendroglial inclusion ratios, but ASO knockdown of SNCA should lower seed amplification signal by at least 50% in all three seed classes.

Proposed experiment: Expose human dopaminergic neuron/oligodendrocyte co-cultures to characterized PD, DLB, and MSA seed extracts; treat with SNCA ASO or control; quantify pS129-SNCA, RT-QuIC/seed amplification, oligodendroglial stress, and neuronal survival.

Cross-disease confidence rationale: Canonical genetics/pathology in PD plus direct MSA glial inclusion evidence.

Internal SciDEX support: SciDEX support query found 44 matching hypotheses across 5 disease labels, including 44 with debate_count > 0.

...

🧬 Mechanism

🔗 Mechanism from KG for SNCA

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    SNCA["SNCA"] -->|cross disease mech| PD["PD"]
    SNCA_1["SNCA"] -->|cross disease mech| DLB["DLB"]
    SNCA_2["SNCA"] -->|cross disease mech| MSA["MSA"]
    h_cross_synth_snca_synucl["h-cross-synth-snca-synucleinopathy"] -->|proposes shared me| SNCA_3["SNCA"]
    style SNCA fill:#4fc3f7,stroke:#333,color:#000
    style PD fill:#ef5350,stroke:#333,color:#000
    style SNCA_1 fill:#4fc3f7,stroke:#333,color:#000
    style DLB fill:#ef5350,stroke:#333,color:#000
    style SNCA_2 fill:#4fc3f7,stroke:#333,color:#000
    style MSA fill:#ef5350,stroke:#333,color:#000
    style h_cross_synth_snca_synucl fill:#4fc3f7,stroke:#333,color:#000
    style SNCA_3 fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix4 supports0 contradicts
Supports
SNCA mutation was identified in familial Parkinson's disease.
1997PMID:9197268high
Supports
Alpha-synuclein is present in Lewy bodies.
1997PMID:9278044high
Supports
Alpha-synuclein immunoreactivity is present in MSA glial cytoplasmic inclusions.
1998PMID:9682846high
Supports
Host cell proteostasis capacity and membrane lipid environment interact to determine whether alpha-synuclein seeds induce neuronal Lewy pathology or oligodendroglial cytoplasmic inclusions.

🏥 Translation

🧬 3D Protein Structure — SNCA

🧬 PDB 1XQ8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SNCA →

No DepMap CRISPR Chronos data found for SNCA.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0004
Events (7d)
1
Price History
▲2.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
Patient-derived alpha-synuclein seeds from PD/DLB and MSA should induce different neuronal-versus-oligodendroglial inclusion ratios, but ASO knockdown of SNCA should lower seed amplification signal byIf this mechanism is real, then Patient-derived alpha-synuclein seeds from PD/DLB and MSA should induce different neuronal-versus-oligodendroglial inclusion rat— no observation —pending0.84
🔮 Falsifiable Predictions (1)
pendingconf 84%
Patient-derived alpha-synuclein seeds from PD/DLB and MSA should induce different neuronal-versus-oligodendroglial inclusion ratios, but ASO knockdown of SNCA should lower seed amplification signal by at least 50% in all three seed classes.
Predicted outcome: If this mechanism is real, then Patient-derived alpha-synuclein seeds from PD/DLB and MSA should induce different neuronal-versus-oligodendroglial inc
Falsification: Falsified if the experiment produces results more than 20% below the predicted effect size
Metadatasource: v1_phase_c_backfill · origin_type: cross_disease_synthesis
sourcev1_phase_c_backfill
origin_typecross_disease_synthesis
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.